InsiderTrades.com logo
WARNING: “Buffett Indicator” flashing for first time in 50 years
From Behind the Markets   |   Ad
Warren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indicates the Oracle of Omaha is quietly preparing for a historic market crash. His most reliable crash indicator - the "Buffett indicator" - just flashed red for the first time in 25 years.
Take these 4 steps today to protect your retirement NOW

Michael Rowe Biography and Net Worth

COO of Eyenovia
  • LinkedIn
  • Phone
  • Email
  • Website


Michael Rowe has been serving as our Vice President, Commercial since October 2019 and, prior to that, since July 2018, as our Vice President, Marketing. From February 2016 to June 2018, Mr. Rowe was head of Global Strategic Marketing, Ophthalmology at Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), where he was responsible for the United States and international commercialization, planning and execution for Rhopressa®, for the lowering of elevated IOP in patients with open-angle glaucoma or ocular hypertension. Previously, he spent 12 years at Allergan plc (NYSE: AGN) in various roles supporting corporate strategic initiatives as well as strategic planning for the company’s worldwide glaucoma franchise, including the development of bimatoprost SR and the global launch of Ganfort® UD. Mr. Rowe also has held senior marketing roles at Bayer Healthcare Pharmaceuticals Inc., Women First HealthCare, Inc. (a former public company) and Pfizer Inc (NYSE: PFE). Mr. Rowe holds an M.Sc. in Human Factors/Experimental Psychology from Rensselaer Polytechnic Institute and a B.A. in Psychology from the State University of New York at Stony Brook.

What is Michael M. Rowe's net worth?

The estimated net worth of Michael M. Rowe is at least $9,382.83 as of August 28th, 2024. Mr. Rowe owns 109,998 shares of Eyenovia stock worth more than $9,383 as of December 21st. This net worth estimate does not reflect any other investments that Mr. Rowe may own. Additionally, Mr. Rowe receives an annual salary of $775,470.00 as COO at Eyenovia. Learn More about Michael M. Rowe's net worth.

How old is Michael M. Rowe?

Mr. Rowe is currently 62 years old. There are 3 older executives and no younger executives at Eyenovia. Learn More on Michael M. Rowe's age.

What is Michael M. Rowe's salary?

As the COO of Eyenovia, Inc., Mr. Rowe earns $775,470.00 per year. Learn More on Michael M. Rowe's salary.

How do I contact Michael M. Rowe?

The corporate mailing address for Mr. Rowe and other Eyenovia executives is 295 MADISON AVENUE SUITE 2400, NEW YORK NY, 10017. Eyenovia can also be reached via phone at (917) 289-1117 and via email at [email protected]. Learn More on Michael M. Rowe's contact information.

Has Michael M. Rowe been buying or selling shares of Eyenovia?

Michael M. Rowe has not been actively trading shares of Eyenovia during the last ninety days. Most recently, on Wednesday, August 28th, Michael M. Rowe bought 27,071 shares of Eyenovia stock. The stock was acquired at an average cost of $0.52 per share, with a total value of $14,076.92. Following the completion of the transaction, the chief executive officer now directly owns 109,998 shares of the company's stock, valued at $57,198.96. Learn More on Michael M. Rowe's trading history.

Who are Eyenovia's active insiders?

Eyenovia's insider roster includes Stuart Grant (Major Shareholder), Tsontcho Ianchulev (CEO), Kenneth Lee, Jr. (Director), Charles Mather, IV (Director), and Michael Rowe (COO). Learn More on Eyenovia's active insiders.

Are insiders buying or selling shares of Eyenovia?

In the last twelve months, Eyenovia insiders bought shares 6 times. They purchased a total of 1,752,939 shares worth more than $1,219,009.44. The most recent insider tranaction occured on August, 28th when CEO Michael M Rowe bought 27,071 shares worth more than $14,076.92. Insiders at Eyenovia own 7.1% of the company. Learn More about insider trades at Eyenovia.

Information on this page was last updated on 8/28/2024.

Michael M. Rowe Insider Trading History at Eyenovia

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/28/2024Buy27,071$0.52$14,076.92109,998View SEC Filing Icon  
8/26/2024Buy50,000$0.57$28,500.0082,927View SEC Filing Icon  
12/4/2023Buy4,890$1.36$6,650.4032,927View SEC Filing Icon  
9/19/2023Buy1,400$1.66$2,324.0028,037View SEC Filing Icon  
9/15/2023Buy1,137$1.75$1,989.7526,637View SEC Filing Icon  
10/27/2021Buy1,200$4.14$4,968.00View SEC Filing Icon  
9/13/2021Buy1,500$4.40$6,600.004,300View SEC Filing Icon  
5/27/2021Buy1,400$4.71$6,594.002,800View SEC Filing Icon  
9/25/2018Buy800$4.23$3,384.00View SEC Filing Icon  
See Full Table

Michael M. Rowe Buying and Selling Activity at Eyenovia

This chart shows Michael M Rowe's buying and selling at Eyenovia by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Eyenovia Company Overview

Eyenovia logo
Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.
Read More

Today's Range

Now: $0.09
Low: $0.08
High: $0.09

50 Day Range

MA: $0.29
Low: $0.08
High: $0.57

2 Week Range

Now: $0.09
Low: $0.08
High: $2.57

Volume

14,142,422 shs

Average Volume

3,200,527 shs

Market Capitalization

$7.37 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.43
WARNING: “Buffett Indicator” flashing for first time in 50 years
From Behind the Markets   |   Ad
Warren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indicates the Oracle of Omaha is quietly preparing for a historic market crash. His most reliable crash indicator - the "Buffett indicator" - just flashed red for the first time in 25 years.
Take these 4 steps today to protect your retirement NOW